Nanochon Completes First Patient Treatment in Clinical Study of Knee Implant
Medical device company Nanochon has treated its first patient with the 3D-printed Chondrograft™ implant for knee cartilage defects.
Nanochon, a company developing medical devices, has successfully treated the first patient in its First-in-Human (FIH) clinical study using its Chondrograft™ implant. This marks a significant milestone in the evaluation of the device for knee cartilage defects.
The Chondrograft™ implant is described as a patented, 3D-printed device designed to address articular cartilage damage in the knee. The FIH study aims to assess the safety and efficacy of this new treatment modality.
This development could offer a new therapeutic option for individuals suffering from knee cartilage injuries, which often lead to pain and reduced mobility. The company's technology focuses on repairing damaged cartilage.
The first patient was treated on September 2, 2026, in Baltimore. Initial reports indicate the procedure was completed successfully.